Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rick A Bright

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Vaccine|August 19, 2008
H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza virusesKutubuddin Mahmood, Rick A Bright, Nutan Mytle, et al.
Lancet (London, England)|October 4, 2005
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernRick A Bright, Marie-jo Medina, Xiyan Xu, et al.
Lancet (London, England)|February 14, 2006
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in miceMary A Hoelscher, Sanjay Garg, Dinesh S Bangari, et al.
The Journal of Infectious Diseases|June 16, 2007
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwideVarough M Deyde, Xiyan Xu, Rick A Bright, et al.
Vaccine|March 6, 2007
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutininRick A Bright, Donald M Carter, Shannon Daniluk, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008Tiffany G Sheu, Varough M Deyde, Margaret Okomo-Adhiambo, et al.
Vaccine|December 17, 2018
Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)Christine M Oshansky, James Zhou, Yonghong Gao, et al.
Plos One|January 31, 2008
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleRick A Bright, Donald M Carter, Corey J Crevar, et al.
Emerging Infectious Diseases|February 9, 2008
Adamantane-resistant influenza infection during the 2004-05 seasonMahbubur Rahman, Rick A Bright, Burney A Kieke, et al.
NPJ Vaccines|March 20, 2021
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adultsChristine M Oshansky, James King, Di Lu, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Vaccine|August 19, 2008
H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza virusesKutubuddin Mahmood, Rick A Bright, Nutan Mytle, et al.
Lancet (London, England)|October 4, 2005
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernRick A Bright, Marie-jo Medina, Xiyan Xu, et al.
Lancet (London, England)|February 14, 2006
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in miceMary A Hoelscher, Sanjay Garg, Dinesh S Bangari, et al.
The Journal of Infectious Diseases|June 16, 2007
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwideVarough M Deyde, Xiyan Xu, Rick A Bright, et al.
Vaccine|March 6, 2007
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutininRick A Bright, Donald M Carter, Shannon Daniluk, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008Tiffany G Sheu, Varough M Deyde, Margaret Okomo-Adhiambo, et al.
Vaccine|December 17, 2018
Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)Christine M Oshansky, James Zhou, Yonghong Gao, et al.
Plos One|January 31, 2008
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particleRick A Bright, Donald M Carter, Corey J Crevar, et al.
Emerging Infectious Diseases|February 9, 2008
Adamantane-resistant influenza infection during the 2004-05 seasonMahbubur Rahman, Rick A Bright, Burney A Kieke, et al.
NPJ Vaccines|March 20, 2021
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adultsChristine M Oshansky, James King, Di Lu, et al.
Pageof 5